Mailhiot SE, Thompson MA, Eguchi AE, Dinkel SE, Lotz MK, Dowdy SF, June RK. The TAT Protein Transduction Domain as an Intra-Articular Drug Delivery Technology.
Cartilage 2021;
13:1637S-1645S. [PMID:
32954793 PMCID:
PMC8804766 DOI:
10.1177/1947603520959392]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE
Intra-articular drug delivery holds great promise for the treatment of joint diseases such as osteoarthritis. The objective of this study was to evaluate the TAT peptide transduction domain (TAT-PTD) as a potential intra-articular drug delivery technology for synovial joints.
DESIGN
Experiments examined the ability of TAT conjugates to associate with primary chondrocytes and alter cellular function both in vitro and in vivo. Further experiments examined the ability of the TAT-PTD to bind to human osteoarthritic cartilage.
RESULTS
The results show that the TAT-PTD associates with chondrocytes, is capable of delivering siRNA for chondrocyte gene knockdown, and that the recombinant enzyme TAT-Cre is capable of inducing in vivo genetic recombination within the knee joint in a reporter mouse model. Last, binding studies show that osteoarthritic cartilage preferentially uptakes the TAT-PTD from solution.
CONCLUSIONS
The results suggest that the TAT-PTD is a promising delivery strategy for intra-articular therapeutics.
Collapse